Russia prepares legislation changes to combat ever greening patents

24 September 2018

GMP News

The Russian Federal Service for Intellectual Property (Rospatent) published a document on amendments to the Rules for drawing up, filing and reviewing documents that are the basis for committing legally significant actions for the state registration of inventions and their forms and Requirements to the documents for an application for grant of a patent for an invention approved by Order of the Ministry of Economic Development of the Russian Federation of 25 May 2016 No. 316.

In the practice of patenting inventions in pharmaceutics, there are inventions that can be categorized as ‘ever greening patents’ if, by this definition, the presumably the same pharmaceutical compositions are understood, but characterized by other features not known from the art.

Such pharmaceutical compositions differ from those known by one or more features, for example, such as:

The essence of the changes introduced is to limit the use of such features when characterizing the pharmaceutical composition in the claims.

The above characteristics according to the changes are not taken into account when assessing patentability for compliance with the condition of patentability “novelty” or “inventive level”. The proposed approach will help avoiding the “double” patenting of already known compositions or their application.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more